We are experienced therapeutic professionals delivering expertise, effective leadership, and strategic operational services to immunology clinical studies.
Our experience in immunology spans early-phase development through successful regulatory submission. This solid experience affords us with a thorough understanding of the treatment communities and patient populations with many key immunology disorders.
We have conducted 100+ immunology studies in recent years in wide-ranging indications. Our successful record of managing immunology clinical development programs has resulted in the approval of five important drugs for which we provided critical services.
Value-added solutions in immunology
Our immunology therapeutic experts review each study proposal and develop recommendations to help our clients achieve their goals, and we have a number of tools to guide our programs:
Novel database analytics to facilitate strategic country and site selection
Country-focused approach to start-up activities and in-depth knowledge of regulatory considerations
Strong relationships with immunology sites, renowned experts, and leading investigators worldwide
An enrollment validation process that yields accurate assessments of site enrollment rates and facilitates patient identification
recruitment and retention
A dedicated patient access group that facilitates recruitment and retention services
Core areas of immunology expertise
In recent years, our clinical development experience has spanned 15 indications, including these core areas:
# Clinical Studies87
Target # Clinical Sites5,200+
Target # Clinical Patients27,200+
Central Review Services
PRA's Central Review Services team, unique in the CRO industry, offers lupus-specific expertise in efficacy endpoint data correlation, standardized…
Ask the Experts: How Do We Control and Prevent Malaria?
In advance of World Malaria Day, we spoke with Darin Seehafer, Director of Therapeutic Expertise, from PRA’s Center for Vaccine Research, and the…
Persistence Leads To High Enrollment
A Phase IV, randomized, single-blind, placebo-controlled, multi-center study to evaluate the immunogenicity of pneumococcal and influenza vaccines in…